Organon & Co. said it entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device contraceptive. Under the terms, Organon will pay $27.5 million at closing, with potential sales-based milestone payments of up to $505 million and tiered double-digit royalties based on net sales, subject to regulatory review and certain conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602230730BIZWIRE_USPR_____20260223_BW700923) on February 23, 2026, and is solely responsible for the information contained therein.